Health Care & Life Sciences » Pharmaceuticals | La Jolla Pharmaceutical Co.

La Jolla Pharmaceutical Co.

La Jolla Pharmaceutical Co.
Stock Exchange NASDAQ Stock Market
EPS
$6.85
Market Cap
$259.88 M
Shares Outstanding
27.1 M
Public Float
23.14 M

Profile

Address
4550 Towne Centre Court
San Diego California 92121
United States
Employees -
Website http://www.lajollapharmaceutical.com
Updated 07/08/2019
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb. LJPC-501 is the proprietary formulation for angiotensin II.

Financials

View All
Created with Highcharts 5.0.14La Jolla Pharmaceutical Co.Net Income. Fiscal year is January-December. All values USD Thousands.17 93517 93521 31321 31341 91241 91278 18578 185114 803114 803199 469199 469201320142015201620172018050k100k150k200k250k
Created with Highcharts 5.0.14La Jolla Pharmaceutical Co.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.00001 0571 0576166160010 05610 05620132014201520162017201802.5k5k7.5k10k12.5k

Kevin C. Tang
Chairman
George Francis Tidmarsh
President, CEO, Secretary & Director